Jump to content

Crotedumab

From Wikipedia, the free encyclopedia
Crotedumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetGCGR
Clinical data
Other namesREGN1193
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6518H10044N1732O2052S46
Molar mass146976.88 g·mol−1

Crotedumab (REGN1193) (INN) is a humanized monoclonal antibody designed for the treatment of diabetes.[1][2]

This drug was developed by Regeneron Pharmaceuticals but is no longer under development.[3]

References

[edit]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Crotedumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  3. ^ Peterson SM, Hutchings CJ, Hu CF, Mathur M, Salameh JW, Axelrod F, Sato AK (April 2023). "Discovery and design of G protein-coupled receptor targeting antibodies". Expert Opinion on Drug Discovery. 18 (4): 417–428. doi:10.1080/17460441.2023.2193389. PMID 36992620.